The study will measure the impact of Cognixion's novel combination of BCI, AI and AR technology on the ability of amyotrophic ...
Positron emission tomography (PET) is a nuclear imaging technique used to diagnose conditions such as cancer. An innovative ...
Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...
Startup Cognixion, which has developed a noninvasive brain-computer interface, has begun a clinical trial for patients with ...
Four immunoassays for neurofilament light chain (NfL) demonstrate consistent performance in patients with amyotrophic lateral ...
Under current regulations, spouses can receive benefits only if the veteran lived with the disability for at least eight years before dying.
AKGsOVIHAMS, a leading healthcare institution, has marked progress in treating ALS using integrative medicine. Known for combining conventional and alternative therapies, the institute has shown ...
A new study compares three types of blood biomarkers: neurofilament light chain proteins, glial acidic proteins and phosphorylated tau 181.
Cognixion announced today that it launched a clinical trial evaluating its integrated, wearable augmented reality and BCI ...
In this week’s InnovationRx newsletter, the worsening measles outbreak, a noninvasive brain-computer implant, replacing heart ...
6h
Zacks.com on MSNIonis Out-Licenses Rights for Rare Blood Cancer Drug to OnoPer the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.
Recent studies have highlighted a link between amyotrophic lateral sclerosis (ALS) and gut microbiota. This prospective study aimed to evaluate the effects of electroacupuncture combined with Chinese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results